Pharmacokinetics (PK) and safety of budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) and glycopyrronium/formoterol fumarate dihydrate (GFF) metered dose inhaler (MDI) in healthy Chinese adults
H. Yu (Shanghai, China), Y. Liu (Shanghai, China), K. Shen (Shanghai, China), P. Assam (Shanghai, China), M. Gillen (Gaithersburg, United States of America), P. Dorinsky (Durham, United States of America)
Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Yu (Shanghai, China), Y. Liu (Shanghai, China), K. Shen (Shanghai, China), P. Assam (Shanghai, China), M. Gillen (Gaithersburg, United States of America), P. Dorinsky (Durham, United States of America). Pharmacokinetics (PK) and safety of budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) and glycopyrronium/formoterol fumarate dihydrate (GFF) metered dose inhaler (MDI) in healthy Chinese adults. 1013
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Relative bioavailability of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) administered with and without a spacer in healthy adults Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019
Development of formoterol fumarate dihydrate powder for inhalation (6 µg and 12 µg per dose) delivered through a multi dose dry powder inhaler (MDPI) Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Pharmacokinetics (PK) of a single dose AZD7594 administered intravenously (IV), orally, and inhaled via two dry powder inhalers (DPI) and a pressurized metered-dose inhaler (pMDI) Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Efficacy and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (GFF MDI) delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe COPD Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018
Systemic bioavailability (BA) and pharmacodynamics (PD) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) or a novel breath-triggered inhaler (BTI) Source: International Congress 2017 – Inhalers and their use Year: 2017
In-use in vitro performance of formoterol fumarate dihydrate powder for inhalation (6 and 12 µg/dose) delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
Efficacy and safety of budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) using co-suspension delivery technology compared to monocomponents and an active comparator in COPD Source: International Congress 2018 – Pharmacological management of COPD Year: 2018
Dosage form proportionality, dose proportionality and pharmacokinetics (PK) of mometasone furoate (MF) and formoterol fumarate (F) from three combination MDI formulations Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
Pharmacodynamic (PD), pharmacokinetic (PK) and safety profile of formoterol delivered via two different dry powder inhalers (DPIs) Source: Eur Respir J 2006; 28: Suppl. 50, 614s Year: 2006
The effect of ketoconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Analysis of exacerbation rates by time interval post-randomization in the KRONOS Phase III study of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Pharmacokinetics (PK) of single doses of mometasone furoate (MF) delivered via the Breezhaler® (BH) and Twisthaler® (TH) devices in healthy subjects Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Dose- and exposure-response modeling to support development of formoterol fumarate (FF) metered dose inhaler (MDI) for COPD Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Comparison of the release characteristics of formoterol dihydrate powder for inhalation delivered through two different types of multidose dry powder inhalers (MDPI) Source: Eur Respir J 2005; 26: Suppl. 49, 126s Year: 2005
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (160/4.5mcg) Spiromax® and BF (200/6mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (320/9mcg) Spiromax® and BF (400/12mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Relative pulmonary bioavailability (BA) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) and a novel breath-triggered inhaler (BTI) Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017